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Available online 25 April 2019Background: Composite clinical worsening (cCW) outcomes might allowmeasurement of disease progression in
paediatric pulmonary arterial hypertension (PAH). This TOPP registry analysis investigated three cCW outcomes
and their predictive strength for lung transplantation/death.
Methods: Patients ≤17 years with idiopathic/familial PAH or PAH-associated congenital heart disease diagnosed
≤3 months before enrolment were included. cCW outcomes included the following variables at enrolment
and/or follow-up: all-cause death, PAH-related hospitalisation, lung transplantation, atrial septostomy (cCW1,
2 and 3), WHO FC deterioration, intravenous/subcutaneous prostanoids initiation, syncope (cCW2,3) and occur-
rence/worsening of ≥2 PAH symptoms (cCW3). The predictive value of CW (excluding transplantation and
death) to transplantation or death was assessed. Predictive values of each cCW for lung transplantation/death
were analysed by Cox proportional hazards models.
Results: From 255 patients, ﬁrst-event rate/100 person-years (95% CI) were cCW1: 23.1(19.3,27.6), cCW2: 43.6
(37.6,50.6), and cCW3: 46.3(40.0,53.7) with PAH-related hospitalisation as the most frequent ﬁrst event in
each. The cCW deﬁnitions comprised from endpoints (excluding transplantation and death), were associated
with higher risk [hazard ratio (95% CI)] for lung transplantation/death [4.23(2.27,7.91), 3.25(1.65,6.39), 2.74
(1.41,5.34), respectively]; individual parameters with higher risks were WHO FC deterioration [3.49
(1.47,8.29)], PAH-related hospitalisation [2.62(1.32,5.20)] and occurrence/worsening of ≥2 PAH symptoms
[2.13(1.02,4.45)].
Conclusions: These data support the use of cCW outcomes in paediatric PAH research. WHO FC deterioration,
PAH-related hospitalisation, occurrence/worsening of ≥2 PAH symptoms may be important for risk assessment
during clinical management.
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Paediatric pulmonary arterial hypertension (PAH) is a serious condi-
tion with signiﬁcant morbidity and mortality, however prognosis has
improved with the use of PAH-speciﬁc therapies approved for use in
adults [1]. As there are multiple similarities between paediatric and
adult patients with PAH [1–3], diagnostic and therapeutic algorithms
used in adult PAH have been adopted, with some adaptations, for dis-
ease management in children, based on small-scale studies and expert
opinion [3,4]. However, there are also important differences betweenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Composite clinical worsening deﬁnitions.
Clinical worsening 1 Clinical worsening 2 Clinical worsening 3
(A) Death (all-cause) (A) Death (all-cause) (A) Death (all-cause)
(B) Lung
transplantation







(D) Atrial septostomy (D) Atrial septostomy (D) Atrial septostomy
(E) WHO FC deteriorationb (E) WHO FC deteriorationb
(F) Initiation of i.v./s.c.
prostanoids (only ﬁrst
event)
(F) Initiation of i.v./s.c.
prostanoids (only ﬁrst
event)
(G) Syncope (G) Syncope
(H) Occurrence/worsening
≥2 PAH symptomsc
i.v., intravenous; PAH, pulmonary arterial hypertension; s.c., subcutaneous; WHO FC,
World Health Organization functional class.
a Increased right-heart failure, haemoptysis.
b Increase ≥1 WHO FC.
c Progression (in patients with symptom at enrolment) and occurrence/progression
(patients without condition at enrolment) of ≥2 symptoms: dyspnoea (includes occur-
rence/progression at rest and progression with exertion in patients with condition at en-
rolment; and occurrence/progression of all dyspnoea in patients without symptom at
enrolment), cyanosis, cough, fatigue, chest pain/discomfort, dizziness and near-syncope
(occurrence only).
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patients are required from real-world evidence and clinical trials.
To assess disease progression, or clinical worsening (CW), in the
paediatric PAH population with the same outcome measure across all
age ranges is more difﬁcult than in adults. For example, 6-minute-
walk distance (6MWD) that is widely used in adult PAH studies tomea-
sure exercise capacity is not a reliable outcome measure in paediatric
studies of young children [3]. Right-sided heart catheterisation (RHC)
is key at diagnosis and beneﬁcial during follow-up in clinical practice
for indications such as clinical deterioration, assessment of treatment
effects, and listing for lung transplantation [1]; however, its use in pae-
diatric clinical trials for the sole purpose of evaluating the efﬁcacy of a
drug is not supported given the risk involved with this invasive proce-
dure [5]. These limitations of applying outcomes appropriate for adults
to the paediatric population need to be overcome. Non-invasive clinical
outcomes tailored for use in paediatric PAH are required in order to as-
sess the efﬁcacy of therapies in a clinical trial setting [6].
The use of composite CW outcomes is increasingly encouraged in
PAH clinical research [7–9]. An evaluation of the Registry to Evaluate
Early and Long-term PAH Disease Management (REVEAL) found that a
composite deﬁnition of time to clinical worsening, and its individual
components, was highly predictive of death in adults [10]. Recent clini-
cal trials of adult PAH therapies have usedmorbidity/mortality compos-
ite endpoints to demonstrate efﬁcacy [11–13]. An observational study
from a Dutch national referral centre including 70 patients reported
on the predictive value of various composite CW deﬁnitions in paediat-
ric PAH [14]. Therefore, we aimed to provide robust evidence that the
use of composite endpoints might also be appropriate in paediatric
PAH research if soft endpoints are revealed to be predictive of the
hard endpoints lung transplantation and death.
Tracking Outcomes and Practice in Pediatric Pulmonary Hyperten-
sion (TOPP) is a global, prospective, non-interventional registry
conducted between January 2008 and July 2015. The registry was de-
signed to provide information about demographics, disease course, treat-
ment, and outcomes in paediatric pulmonary hypertension (PH) [15].
The objective of the current analysis of the TOPP registry was to evaluate
the frequency of CW events using three different composite CW deﬁni-
tions in newly diagnosed (incident) childrenwith PAH, and to determine
the predictive values of these CW deﬁnitions as well as their individual
components for lung transplantation or death in this population.
2. Methods
2.1. Study design and patient population
The design of TOPP has been reported in detail previously [15]. In brief, TOPP enrolled
patients with RHC-conﬁrmed PAH (World Symposium on Pulmonary Hypertension
[WSPH] group 1) or (World Health Organization) WHO group 3–5 PH, aged from
3 months to 18 years, with increased pulmonary vascular resistance and normal left-
sided ﬁlling pressures. The TOPP protocolwas approved by the institutional reviewboards
and ethics committees of the centres contributing to the registry. Patient and/or parental
consentwas obtained for all patients. The authors had full access to all data and agree to be
accountable for its integrity and analysis.
The current analysis included solely incident (diagnosis ≤3months before enrolment)
patients aged ≤17 years at diagnosis and enrolment, with idiopathic PAH (IPAH), familial
PAH (FPAH) or PAH associated with congenital heart disease (APAH-CHD). Patients with
APAH-CHD included those with an open, clinically signiﬁcant, congenital systemic-to-
pulmonary shunt (unrepaired, or repaired but with a substantial residual shunt), a
corrected (closed) congenital systemic-to-pulmonary shunt, or with CHD that had never
been associated with a congenital systemic-to-pulmonary shunt (i.e. transposition of the
great arteries ﬂowing arterial switch) [15]. In addition, patients had to have at least one
follow-up visit at any time after enrolment to be included in the analysis.
2.2. Variables
The following variables selected for the presented researchwere collected in the TOPP
registry at enrolment and/or during follow-up: demographics (age, sex); disease charac-
teristics: WHO functional class (WHO FC), presence/history, occurrence or progression
of symptoms (dyspnoea, cyanosis, cough, fatigue, chest pain/discomfort, dizziness, near-
syncope); PAH-related hospitalisations (hospitalisations because of increased right-
sided heart failure or haemoptysis); occurrence of syncope; initiation of intravenous/subcutaneous prostanoids; atrial septostomy; lung transplantation; and death. The com-
posite CW deﬁnitions included the disease variables summarised in Table 1 and named
CW 1, 2, and 3. WHO FC deterioration was deﬁned as a numerical increase of ≥1 FC, and,
under this deﬁnition, patients classiﬁed as FC IV were not able to deteriorate further.2.3. Statistical analysis
Descriptive statistics were used, including mean, SD, median, lower (Q1) and upper
(Q3) quartiles,minimumandmaximumfor continuous variables, and counts and percent-
ages for categorical variables. Rates for ﬁrst events occurring after enrolment were calcu-
lated, where the denominator was time at risk, deﬁned as person-years observation time
until the ﬁrst event. For the composite CWdeﬁnition, the event rate per 100 person-years
was calculated using the ﬁrst event to occur among all the components. Kaplan-Meier es-
timates were conducted for time to ﬁrst CW1, CW2, and CW3 events.
Factors predictive of lung transplantation or death were identiﬁed by Cox propor-
tional hazardsmodels. In order to evaluate the predictive value of the three CWdeﬁnitions
for lung transplantation or death, these two componentswere removed from the compos-
ite and these CW deﬁnitions were named CW1′, CW2′ and CW3′.
First, the individual component variables at diagnosis were assessed (Table 1: E, F, G,
and H) in univariate models.
Second, univariate andmultivariate models of the ﬁrst event of individual components
(Table 1: C, D, E, F, G, H) were used. The survival timewas determined in a time-dependent
manner, starting at the time of the ﬁrst event of the CW′ component. Multivariate models
included only variables with p b 0.15 in the univariate models. A subgroup univariate anal-
ysis was conducted according to PAH aetiology (IPAH/FPAH and APAH-CHD).
Statistical analyses were carried out using SAS v9.4 (SAS Institute, Cary, NC, USA).3. Results
The analysis included 255 incident patients with PAH - 159 patients
with IPAH/FPAH and 96 patients with APAH-CHD - from 34 centres in
20 countries (Supplemental material: Appendix). Patients were mostly
female (60%) and had a median (Q1, Q3) age of 7 (3, 13) years of age at
diagnosis. TheWHO FC distribution at diagnosiswas: FC I 33 (13%), FC II
109 (43%), FC III 87 (34%), and FC IV 24 (9%); two patients had missing
WHO FC. The median (Q1, Q3) time between diagnosis and enrolment
into TOPP was 0 (0, 1) months, and the median (Q1, Q3) observation
time in TOPP was 33 (12, 55) months. At enrolment, 30 (12%) patients
initiated intravenous/subcutaneous prostanoids. Presence/history of
syncopewas reported in 22 (9%) patients once, in 34 (13%) patients sev-
eral times, in four (2%) patients regularly, and the information was
missing in two (1%) patients. Presence/history of ≥2 PAH symptoms
was reported in 51 (20%) patients. Patient demographics and disease
characteristics at enrolment for the two subgroups IPAH/FPAH and
APAH-CHD are presented in Table 2.
Table 2





Female, n (%) 103 (65) 50 (52)
Median age at diagnosis (Q1, Q3), years 8 (3, 13) 5 (2, 12)
WHO FC, n (%)
I 17 (11) 16 (17)
II 66 (42) 43 (45)
III 55 (35) 32 (33)
IV 19 (12) 5 (5)
Missing 2 0
Median observation period (Q1, Q3), months 33 (12, 50) 34 (14, 58)
Median time from diagnosis to enrolment
(Q1, Q3), months
0 (0, 1) 0 (0, 1)
Initiation of i.v./s.c. prostanoids, n (%) 29 (18) 1 (1)
Syncope
Never 104 (66) 89 (93)
Once 17 (11) 5 (5)
Several times 32 (20) 2 (2)
Regularly 4 (3) 0 (0)
Missing 2 0
Patients with presence/history ≥2 PAH symptoms, n (%) 39 (25) 12 (13)
Percentages are based on the number of patients (n) in the analysis set and groups/sub-
groups with non-missing data. APAH-CHD, pulmonary arterial hypertension associated
with congenital heart disease; IPAH/FPAH, idiopathic pulmonary arterial hypertension/fa-
milial pulmonary arterial hypertension; i.v., intravenous; PAH, pulmonary arterial hyperten-
sion; Q, quartile; s.c., subcutaneous; WHO FC, World Health Organization functional class.
Table 4
Predictive factors for lung transplantation or death in the overall population.
Hazard ratio 95% CI p-Value
Prognostic factors at diagnosis for lung transplantation or death (univariate)
WHO FC (III vs. I/II)a 1.93 1.07–3.49 0.03
WHO FC (IV vs. I/II)a 1.33 0.45–3.89 0.60
Presence/history of ≥2 PAH symptoms 1.22 0.69–2.18 0.50
Syncope (regularly vs. never)a 1.16 0.16–8.47 0.88
Syncope (once vs. never)a 0.92 0.33–2.57 0.87
Syncope (several times vs. never)a 0.90 0.38–2.12 0.80
Initiation of i.v./s.c. prostanoids 0.69 0.25–1.91 0.47
Prognostic value of component's ﬁrst events for lung transplantation or death:
individual disease variables (univariate)
WHO FC deterioration 6.70 3.12–14.36 b0.0001
Occurrence/worsening of ≥2 PAH symptoms 4.77 2.54–8.97 b0.0001
Initiation of i.v./s.c. prostanoids 4.59 2.13–9.87 b0.0001
PAH-related hospitalisation 4.22 2.26–7.89 b0.0001
Occurrence of syncope 2.34 0.94–5.81 0.07
Prognostic value of component's ﬁrst events for lung transplantation or death:
individual disease variables (multivariate)b
WHO FC deterioration 3.49 1.47–8.29 b0.01
PAH-related hospitalisation 2.62 1.32–5.20 b0.01
Occurrence/worsening ≥2 PAH symptoms 2.13 1.02–4.45 0.045
Prognostic value of composite clinical worsening outcomes for lung
transplantation or death (univariate)c
Clinical worsening 1 4.23 2.27–7.91 b0.0001
Clinical worsening 2 3.25 1.65–6.39 b0.001
Clinical worsening 3 2.74 1.41–5.34 b0.01
CI, conﬁdence interval; i.v., intravenous; PAH, pulmonary arterial hypertension; s.c., sub-
cutaneous; WHO FC, World Health Organization functional class.
a Data are missing for two patients.
b Multivariate analysis conducted on variables with p b 0.15 in univariate models.
c Lung transplantation and death were removed from the analysis of the clinical wors-
ening composite endpoints.
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ﬁrst-event rate (95% conﬁdence interval [CI]) for CW1 was 23.1
(19.3–27.6) per 100 person-years (121 events over 524.7 person-
years). For CW2, the ﬁrst-event rate almost doubled to 43.6
(37.6–50.6) per 100 person-years (173 events over 396.5 person-
years) with the additional components E, F, G (WHO FC deterioration,
initiation of intravenous/subcutaneous prostanoids and syncope;
Table 1) added. The ﬁrst-event rate for CW3 was 46.3 (40.0–56.7) per
100 person-years (175 events over 396.5 person-years) with the ﬁnal
component H (PAH symptoms; Table 1) added. The respective
Kaplan-Meier estimate analysis showed that at 6, 12, and 18 months a
ﬁrst CW1 event (95% CI) was experienced by 23.6% (18.8–29.4), 31.5%
(26.0–37.7), and 36.9% (31.1–43.5) patients, respectively; a ﬁrst CW2
event was experienced by 30.1% (24.8–36.2), 41.7% (35.8–48.2), and
54.9% (48.6–61.5) patients, respectively; and a ﬁrst CW3 event was ex-
perienced by 33.3% (27.8–39.5), 44.5% (38.5–51.0), and 57.3%
(50.9–63.7) patients, respectively.
PAH-related hospitalisation was the most frequent ﬁrst event in
CW1, with a ﬁrst-event rate of 17.9 (14.6–21.9) per 100 person-years,Table 3
Summary of composite clinical worsening deﬁnitions.
Clinical worsening 1
(N = 255)
Number of events 121
Person-years 524.7
First-event ratea (95% CI) 23.1 (19.3–27.6)
First event in the respective composite deﬁnition n Event ratea 95% CI
Death
All-cause 16 3.0 (1.9–5.0)
PAH-related 9 1.7 (0.8–3.3)
PAH-related hospitalisation 94 17.9 (14.6–21.9
Transplantation 1 0.2 (0.0–1.1)
Atrial septostomy 1 0.2 (0.0–1.1)
Deterioration in WHO FC – – –
Initiation of i.v./s.c. prostanoids – – –
Syncope – – –
Occurrence/worsening ≥2 PAH symptoms – – –
CI, conﬁdence interval; i.v., intravenous; PAH, pulmonary arterial hypertension; s.c., subcutane
a Rate per 100 person-years.followed by all-cause death (3.0 (1.9–5.0) per 100 person-years) and
PAH-related death (1.7 (0.8–3.3) per 100 person-years). PAH-related
hospitalisation and WHO FC deterioration were the most frequent ﬁrst
events in CW2, with ﬁrst-event rates of 17.9 (14.2–22.6) and 16.6
(13.1–21.2) per 100 person-years, respectively, and in CW3, with ﬁrst
event rates of 16.2 (12.6–20.8) and 15.4 (11.9–19.9) per 100 person-
years, respectively. Atrial septostomy occurred as the ﬁrst event in
only one patient.
When evaluating factors predictive of lung transplantation or death
in a univariate analysis, patients with WHO FC III at diagnosis were at
signiﬁcantly higher risk than patients with WHO FC I/II; hazard ratio






43.6 (37.6–50.6) 46.3 (40.0–53.7)
n Event ratea 95% CI n Event ratea 95% CI
14 3.5 (2.1–6.0) 14 3.7 (2.2–6.3)
8 2.0 (0.9–4.0) 8 2.1 (0.9–4.2)
) 71 17.9 (14.2–22.6) 61 16.2 (12.6–20.8)
1 0.3 (0.0–1.4) 1 0.3 (0.0–1.5)
1 0.3 (0.0–1.4) 1 0.3 (0.0–1.5)
66 16.6 (13.1–21.2) 58 15.4 (11.9–19.9)
4 1.0 (0.3–2.6) 4 1.1 (0.3–2.7)
8 2.0 (0.9–4.0) 7 1.9 (0.7–3.8)
– – – 21 5.6 (3.6–8.5)
ous; WHO FC, World Health Organization functional class.
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dependent manner. In the univariate analysis of the ﬁrst event of indi-
vidual components (Table 1: C, D, E, F, G, H), WHO FC deterioration
had the strongest predictive value for lung transplantation or death
(HR, 6.70; 95% CI, 3.12–14.36), followed by occurrence/worsening of
≥2 PAH symptoms (HR, 4.77; 95% CI, 2.54–8.97), and initiation of intra-
venous/subcutaneous prostanoids (HR, 4.59; 95% CI, 2.13–9.87); all p b
0.0001 (Table 4). In multivariate analysis, a ﬁrst event of WHO FC dete-
rioration (HR, 3.49; 95% CI, 1.47–8.29), PAH-related hospitalisation (HR,
2.62; 95% CI, 1.32–5.20), and occurrence or worsening of ≥2 PAH symp-
toms (HR, 2.13; 95% CI, 1.02–4.45) were signiﬁcant independent risk
factors for lung transplantation or death (Table 4).
All three CW′deﬁnitions (excluding the components lung transplan-
tation and death) were associated with a signiﬁcantly higher risk for
lung transplantation or death (Table 4).
Predictive models for lung transplantation or death according to
aetiology are shown in Supplementary Table 1. For the subgroup of pa-
tients with IPAH/FPAH (n= 159), the univariate andmultivariate anal-
yses found results similar to those in the overall population. However,
for the subgroup of patients with APAH-CHD (n = 96), none of the
CW deﬁnitions or individual components were signiﬁcant predictive
factors for lung transplantation or death (Supplementary Table 1).
4. Discussion
The current analysis, using data from the TOPP registry, a large co-
hort of paediatric patients with PAH, primarily aimed to create and de-
termine the predictive value of a CW endpoint (including death and
transplantation) that could be used in clinical trials. The analysis also
describes the relevance of composite CW deﬁnitions (excluding death
and transplantation) to predict lung transplantation or death, which
could be used for future prognostic studies and to identify patients
with a higher risk of disease progression. The CW deﬁnitions comprised
a combination of disease variables. All-cause death, PAH-related
hospitalisation (owing to increased right-sided heart failure or
haemoptysis), lung transplantation, and atrial septostomy were in-
cluded in all three CW deﬁnitions, with the addition of WHO FC deteri-
oration, initiation of intravenous/subcutaneous prostanoids and
syncope to CW2 and CW3, and occurrence or worsening of ≥2 PAH
symptoms to CW3. These CW deﬁnitions were designed to evaluate
the differences in the proportion of events during follow-up when
more subjective clinical outcomes were introduced into the deﬁnition.
Furthermore, this analysis assessed the predictive value of the individ-
ual disease variables and the CW′ deﬁnition (excluding lung transplan-
tation and death) for lung transplantation or death.
Our ﬁrst interesting result is that the number of events in a paediat-
ric cohort of PAH is high regardless of the CW deﬁnition used. As ex-
pected, the number of events increases when more subjective clinical
outcomes are included in the CW deﬁnition. The observed event rate,
ranging from 23.1 to 46.3 per 100 person-years is consistent with an
earlier study of 70 patients with paediatric PAH that showed the num-
ber of clinical events was high in the study population, when consider-
ing a composite deﬁnition of death, lung transplantation, PAH-related
hospitalisation, initiation of intravenous prostanoids and functional de-
terioration (WHO FC and/or 6MWD) [14].
The second interesting result is the frequency of ﬁrst CW event, in
this population of incident patients. This high frequency of events and
their precocity are valuable information for designing future trials as
paediatric PAH is a rare and heterogeneous disease, and reducing the
need for large cohorts of patients to evaluate the efﬁcacy of a new com-
pound or treatment strategy is a crucial issue. Knowing the frequency
and timing of CWevents is important information for sample size calcu-
lation of future trials.
The third notable ﬁnding generated by the current study is the pre-
dictive value of individual disease variablesWHOFCdeterioration, PAH-
related hospitalisation, and the occurrence or worsening of ≥2 PAHsymptoms. These three variables were predictive of lung transplanta-
tion or death in both theunivariate andmultivariatemodels. Theseﬁnd-
ings are consistent with and expand upon the results of the national
Dutch cohort study that found FC deterioration to be predictive of
lung transplantation or death in paediatric PAH [14,16]. They are also
in agreement with an analysis of adult patients with PAH that found re-
duced survival in patients with unchanged or worsened WHO-FC com-
pared with patients whose WHO FC improved [17]. Furthermore, the
results from the current analysis provide evidence for the ﬁrst time
that the occurrence or progression of ≥2 PAH symptoms is predictive
of lung transplantation or death in paediatric PAH. We also show here
that PAH-related hospitalisation was the most frequent ﬁrst event in
the CW deﬁnitions, similar to the ﬁndings in adult PAH trials that have
used composite morbidity/mortality endpoints including PAH-related
hospitalisation. Hospitalisation for PAH deterioration is certainly an im-
portant factor as mortality is higher in paediatric patients who are
hospitalised for PH compared with general paediatric hospitalisations
[18]. An analysis of the REVEAL cohort found ﬁrst PAH-related
hospitalisations to be more frequent in adult than paediatric PAH
patients, and predictive of subsequent rehospitalisation and poorer
3-year survival [19]. It is of note that the paediatric REVEAL analysis in-
cluded mainly prevalent patients diagnosed during childhood. The cur-
rent study only included incident patients; therefore, our ﬁndings are
potentially more robust for predicting long-term outcomes, as the im-
pact of a survival bias is minimised compared with prevalent cohorts.
Syncope was not found to be predictive of lung transplantation or
death in this cohort, which is in line with results of previous cohort
studies [20,21]. Recently, in a small study of 55 paediatric patients
with PAH, although the absence of syncope was linked to improved
prognosis, the presence of syncopewasnot considered to be a risk factor
for lung transplantation or death [22]. We believe that this information
has a clinical importance for the decision to escalate therapy. Indeed, the
practice of prescribing an additional drug or recommending a paediatric
patient for lung transplantation when syncope recurs should certainly
be reviewed in the light of these ﬁndings.
Composite CW endpoints have been adopted in recent clinical trials
of adult PAH therapies as morbidity/mortality endpoints [11–13], and
their use is being encouraged in paediatric PAH clinical trials [2,5,23].
Analysis of composite CW endpoints has always been a challenge be-
cause of the lack of a standardised deﬁnition [24,25]. The current
study evaluated the relevance of three different deﬁnitions. Interest-
ingly, all three CW composite outcomes were signiﬁcantly predictive
of lung transplantation or death. This was in agreement with the ﬁnd-
ings of a recent cohort study of paediatric patients in the Netherlands
[14]. These current analyses may inform the design and sample size cal-
culation of future paediatric PAH trials and support the use of a compos-
ite CW endpoint in those trials. Indeed, the ﬁrst paediatric trial
incorporating these composite endpoints in the design was initiated in
2017 [26].
Comparedwith results in the overall population, similar resultswere
observed in the subgroup of patients with IPAH/FPAH, with an even
greater predictive value of lung transplantation or death for several of
the individual disease variables (Supplementary Table 1). Conversely,
no signiﬁcant predictors of lung transplantation or death could be iden-
tiﬁed in the APAH-CHD subgroup. However, this subgroup included het-
erogeneous underlying CHD physiologies and the number of outcome
events was small, which contributed to the wide CIs. Indeed, patients
with Eisenmenger physiology have different survival outcomes than
those with a closed shunt and PAH [27–29]. Identifying speciﬁc predic-
tors in subsets with APAH-CHD would require large patient numbers
and, potentially, other factors in the predictive model, such as the type
of shunt (pre- or post-tricuspid), and the type of underlying CHD.
The ﬁndings of the current study deﬁne a clinical endpoint for fur-
ther use in clinical trials. A PAH worsening deﬁnition based on occur-
rence or progression of symptoms may be predictive for death and
lung transplantation, and therefore could be used for prognostic studies
114 M. Beghetti et al. / International Journal of Cardiology 289 (2019) 110–115and in clinical practice to identify patients at higher risk of disease pro-
gression and poorer outcomes. The current study identiﬁed the occur-
rence of symptoms as a reliable predictor of outcomes in paediatric
PAH. The different CW deﬁnitions may be useful for risk stratiﬁcation
of a patient during follow-up.
4.1. Limitations
There are certain limitations to this study inherent to observational
studies. Further analyses are warranted including analysis for compet-
ing risks, adjustment for treatment patterns and other potential con-
founders. Such additional analysis could be considered based on an
updated cohort from the TOPP registry as well as from controlled clini-
cal trials. The study only deﬁned PAHworsening and not PAH improve-
ment. This informationwould have been important to further guide the
management of these patients in clinical practice, and to facilitate the
design of future paediatric PAH trials. Similarly, therapeutic targets
were not conﬁrmed in this cohort. These targets are scarcely identiﬁed
in paediatric PAH [16]. The Dutch cohort found that improvements in
WHO FC, N-terminal brain pronatriuretic peptide, and tricuspid annular
plane systolic excursion after treatment are associated with better sur-
vival [16]. The learnings from the TOPP-1 registry have informed the on-
going TOPP-2 registry [30], which aims to further develop treatment
goals that were proposed at the 2013 World Symposium on PH [1], as
well as to identify new treatment goals. This database will focus more
on the collection of follow-up variables, such as NT-proBNP, which
have become important for risk assessment in recent years and may
provide further analysis of the associations between these variables
and clinical endpoints.
5. Conclusions
The results from this analysis of the TOPP registry suggest that differ-
ent CW deﬁnitions could be used as primary endpoints in future paedi-
atric PAH trials and prognostic studies. Indeed, the number of events
according to the different deﬁnitions is high and the events occur
early in the course of the disease, suggesting that the number of patients
needed to be included in randomised control trials could be reduced
comparedwith the event-driven trials in adult PAH [12,31]. In addition,
WHO FC deterioration, PAH-related hospitalisation, and occurrence or
worsening of ≥2 PAH symptoms are predictive of lung transplantation
or death. These ﬁndings are of importance for individual monitoring
as well as for the individual risk assessment and therapeutic decisions
during follow-up in paediatric PAH patients.
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